Ionis Pharmaceuticals (IONS) Set to Announce Quarterly Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of ($1.16) per share for the quarter. Ionis Pharmaceuticals has set its FY 2024 guidance at EPS.Parties that wish to register for the company’s conference call can do so using this link.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.47. Ionis Pharmaceuticals had a negative return on equity of 115.66% and a negative net margin of 44.90%. The business had revenue of $225.00 million for the quarter, compared to the consensus estimate of $152.35 million. During the same period in the prior year, the business earned $0.60 EPS. The firm’s revenue for the quarter was up 19.7% on a year-over-year basis. On average, analysts expect Ionis Pharmaceuticals to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Ionis Pharmaceuticals Stock Down 1.6 %

IONS stock opened at $39.71 on Wednesday. The stock’s 50 day simple moving average is $42.14 and its 200 day simple moving average is $43.07. Ionis Pharmaceuticals has a fifty-two week low of $35.95 and a fifty-two week high of $54.44. The company has a debt-to-equity ratio of 4.67, a quick ratio of 7.51 and a current ratio of 7.61. The company has a market cap of $5.80 billion, a P/E ratio of -14.87 and a beta of 0.38.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Guggenheim decreased their price objective on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, October 9th. StockNews.com lowered Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, October 25th. TD Cowen boosted their price objective on Ionis Pharmaceuticals from $54.00 to $59.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. The Goldman Sachs Group boosted their price objective on Ionis Pharmaceuticals from $33.00 to $37.00 and gave the stock a “sell” rating in a report on Friday, August 2nd. Finally, Leerink Partners raised Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $53.00 to $62.00 in a report on Wednesday, July 24th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.28.

Insider Activity at Ionis Pharmaceuticals

In related news, EVP Richard S. Geary sold 2,430 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $48.00, for a total value of $116,640.00. Following the transaction, the executive vice president now owns 85,508 shares in the company, valued at approximately $4,104,384. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders have sold 2,803 shares of company stock worth $134,402. Insiders own 2.71% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.